Autogenomics

The designation will help the company accelerate the process of bringing the opioid addiction risk test through regulatory review and clearance.

The company joins others in a still-controversial setting, hoping to market its test to help guide the prescription of narcotic pain medications.

The companies will also collaborate on new diagnostic technologies and products that are specifically designed for Chinese patients.

The firm will withdraw its planned IPO after being told that it would have to take a 30 to 40 percent discount to its valuation, its CEO said. 

The company said it plans to offer 3.75 million shares of its common stock and expects to fetch between $11 and $13 per share in its IPO.

NEW YORK (GenomeWeb) – Molecular diagnostics firm AutoGenomics has refiled for an initial public offering, less than one year after it pulled earlier plans to go public.

NEW YORK (GenomeWeb) – Molecular diagnostics firm AutoGenomics and personalized healthcare company Genomas have signed an agreement to develop genetic tests and DNA-guided diagnostic systems to aid in the selection of statins to improve treatment of heart disease, obesity, and diabetes.

Korea Institute of Science and Technology has been awarded

NEW YORK (GenomeWeb News) – Molecular diagnostics firm AutoGenomics filed with the US Securities and Exchange Commission to officially withdraw a planned initial public offering.

Pages

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.